These JAK2 translocations (e.g., PCM1-JAK2, ETV6-JAK2, and BCR-JAK2) and FLT3 translocations (e.g., ETV6-FLT3, BCR-FLT3, and FLT3-TRIP11) are less common than PDGFRB translocations, generally manifesting as chronic myeloproliferative disease (e.g., CEL, aCML or CMML with eosinophilia), acute lymphoblastic leukemia, and very rarely as AML with eosinophilia. This evidence concerns the gene JAK2 and chronic myelomonocytic leukemia.